Unique ID issued by UMIN | UMIN000022304 |
---|---|
Receipt number | R000025437 |
Scientific Title | Evaluation of neoadjuvant chemotherapy for breast cancer using contrast-enhanced ultrasound (CE-US) imaging |
Date of disclosure of the study information | 2016/05/13 |
Last modified on | 2017/05/19 13:30:12 |
Evaluation of neoadjuvant chemotherapy for breast cancer using contrast-enhanced ultrasound (CE-US) imaging
Evaluation of neoadjuvant chemotherapy for breast cancer using CE-US imaging
Evaluation of neoadjuvant chemotherapy for breast cancer using contrast-enhanced ultrasound (CE-US) imaging
Evaluation of neoadjuvant chemotherapy for breast cancer using CE-US imaging
Japan |
breast cancer
Breast surgery | Radiology |
Malignancy
NO
To evaluate the effectiveness of contrast-enhanced ultrasound to evaluate the change of perfusoin during neoadjuvant chemotherapy for breast cancer.
Efficacy
Exploratory
To compare the quantitative parameters from contrast-enhanced ultrasound in pre-, 3 weeks, 12 weeks and 21 weeks after NAC between responders and non-responders.
1.To evaluate the possibility of non-contrast Doppler ultrasound imaging to evaluate the effectiveness of NAC.
2. To evaluate the possibility of contrast-enhanced and non-contrast Doppler ultrasound imaging to evaluate the effectiveness of NAC in lymph node metastases.
3. To evaluate the possibility of diffusion weighted imaging and dynamic contrast-enhanced imaging from MRI to evaluate the effectiveness of NAC in primary breast cancer lymph node metastases.To evaluate which parameters from contrast-enhanced ultrasound or MRI would be the best to predict the effectiveness of NAC.
Observational
20 | years-old | <= |
80 | years-old | > |
Female
Patients who are performed neoadjuvant chemotherapy before surgery for breast cancer will be included if informed consent will be obtained.
The diagnosis of breast cancer will be made using imaging findings including mammography, non-contrast enhanced ultrasound and dynamic MRI and needle biopsy.
The objective of this study is one lesion which can be detected by B-mode ultrasound clearly from each patient. In patients with multiple or bilateral lesions, the lesion with largest diameter will be targeted.
Exclusion criteria is
1. Patients who are pregnant or breast-feeding.
2. Patients who have allergy to Sonazoid.
3. Patients who have allergy to egg.
4. Patients who have pulmonary arteriovenous shunt or right-to-left shunt.
5. Patients who have severe heart or lung disease.
6. Patients to whom contrast-enhanced CT or MRI can not be performed due to renal failure.
7. Patients who have mental disease.
40
1st name | |
Middle name | |
Last name | Naoko Mori |
Tohoku Univesity
Diagnostic Radiology
1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi
022-717-7312
naokomori7127@gmail.com
1st name | |
Middle name | |
Last name | Naoko Mori |
Tohoku Univesity
Diagnostic Radiology
1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi
022-717-7312
naokomori7127@gmail.com
Diagnosis Radiology of Tohoku University
Kakenhi
Japanese Governmental office
NO
2016 | Year | 05 | Month | 13 | Day |
Unpublished
Preinitiation
2016 | Year | 04 | Month | 26 | Day |
2016 | Year | 05 | Month | 01 | Day |
This study is a observatory study to evaluate the effectiveness of quantative analysis for contrast enhanced ultrasound for patients who will be performed with neoadjuvant chemotherapy before surgery.
2016 | Year | 05 | Month | 13 | Day |
2017 | Year | 05 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025437
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |